Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

BACKGROUND: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted...

Descripción completa

Detalles Bibliográficos
Autores principales: Diago-Sempere, Elena, Bueno, José Luis, Sancho-López, Aránzazu, Rubio, Elena Múñez, Torres, Ferrán, de Molina, Rosa Malo, Fernández-Cruz, Ana, de Diego, Isabel Salcedo, Velasco-Iglesias, Ana, Payares-Herrera, Concepción, Flecha, Inmaculada Casas, Avendaño-Solà, Cristina, Palomino, Rafael Duarte, Ramos-Martínez, Antonio, Ruiz-Antorán, Belén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816149/
https://www.ncbi.nlm.nih.gov/pubmed/33472681
http://dx.doi.org/10.1186/s13063-020-05011-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816149/
https://www.ncbi.nlm.nih.gov/pubmed/33472681
http://dx.doi.org/10.1186/s13063-020-05011-9

Ejemplares similares